Cabaletta Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CABA research report →
Range $3 – $32
Price Chart
About the company
Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies.
- CEO
- Steven A. Nichtberger
- IPO
- 2019
- Employees
- 156
- HQ
- Philadelphia, PA, US
Get TickerSpark's AI analysis on CABA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $520.14M
- P/E
- -2.02
- Fwd P/E
- 4.09
- PEG
- -0.03
- P/S
- 0.00
- P/B
- 2.29
- EV/EBITDA
- -1.81
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -128.27%
- ROIC
- -78.51%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-172,241,000
- Net Income
- $-167,856,000-44.9%
- EPS
- $-1.64+29.9%
- OCF Growth
- -48.6%
- FCF Growth
- -46.3%
- 52W High
- $4.23
- 52W Low
- $1.40
- 50D MA
- $2.88
- 200D MA
- $2.87
- Beta
- 3.25
- RSI (14)
- 66
- Avg Volume
- 4.60M
No earnings-call transcripts are available for CABA yet.
- Free Float
- 87.6%
- Shares Outstanding
- 163.05M
- Float Shares
- 142.90M
of shares held by institutions
98 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 4.42M | ▲ 228.70K |
| Two Sigma Advisers, LP | 737.90K | ▲ 406.90K |
| Cubist Systematic Strategies, LLC | 37.74K | ▼ 197.53K |
| Point72 Asia (Singapore) Pte. Ltd. | 8.94K | ▼ 25.83K |
Held by 123 ETFs
Biggest fund positions in CABA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 9, 26 | Tomasello Shawn | other | 22,000 |
| Jun 9, 26 | Simon Mark | other | 22,000 |
| Jun 9, 26 | HENRIQUES RICHARD C JR | other | 22,000 |
| Jun 9, 26 | Bollard Catherine | other | 22,000 |
| Jun 9, 26 | Brun Scott C. | other | 22,000 |
| Mar 2, 26 | Das Arun | other | 175,000 |
| Mar 2, 26 | Gerard Michael | other | 175,000 |
| Mar 2, 26 | Binder Gwendolyn | other | 225,000 |
| Mar 2, 26 | Chang David J. | other | 225,000 |
| Mar 2, 26 | Nichtberger Steven | other | 674,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CABA coverage
Recent articles, reports, and earnings notes.
No research on CABA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CABA report →Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · Aug 13
Cabaletta Bio: The Market Sold The EULAR News, I'm Buying
seekingalpha.com · Jun 26
Cabaletta Bio, Inc. (CABA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
seekingalpha.com · Jun 8
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress
globenewswire.com · Jun 3
Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year?
zacks.com · May 20
Cabaletta Bio (CABA) Upgraded to Buy: Here's Why
zacks.com · May 18
Cabaletta Bio Q1 Earnings: More Positive Data Suggests CAR-T Can Work In Autoimmune
seekingalpha.com · May 14
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · May 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.